GlassScriptPhysician profile
Christopher S Yuvienco
NPI 1659316925
$5,403.95
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $2,212 · 2021: $796 · 2022: $353 · 2023: $519 · 2024: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.35 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $963.31 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $626.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $502.32 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $479.69 | 2019-2024 | Rybelsus |
| Pfizer INC. | $372.99 | 2019-2021 | |
| Amgen INC. | $282.53 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $267.48 | 2019-2021 | |
| Amarin Pharma, INC. | $247.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $232.80 | 2019-2021 | |
| Lilly USA, LLC | $228.39 | 2019-2021 | |
| Abbvie INC. | $158.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $157.83 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $126.07 | 2020 | |
| Biodelivery Sciences International, INC. | $124.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $97.98 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $82.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.85 | 2020-2021 | |
| Antares Pharma, INC. | $56.63 | 2019-2020 | |
| Mylan Specialty L.P. | $46.56 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $42.12 | 2020-2021 | |
| Esperion Therapeutics, INC. | $24.81 | 2020 | |
| Abbott Laboratories | $23.61 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.88 | 2019 | |
| Opko Pharmaceuticals, LLC | $19.36 | 2021 | |
| Radius Health, INC. | $18.74 | 2019 | |
| Circassia INC. | $18.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2020 | |
| Pbg Puerto Rico LLC | $17.81 | 2021 | |
| Astellas Pharma US INC | $17.27 | 2021 | |
| Genentech USA, INC. | $16.05 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 2019 | |
| Dexcom, INC. | $12.32 | 2021 | |
| Gilead Sciences, INC. | $12.16 | 2019 | |
| Mannkind Corporation | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yuvienco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.